Marinomed Biotech AG (VSE:MARI), an Austrian science-based biotech company with globally marketed therapeutics, reported today its financial results for the first quarter of 2022.
“We are proud to report again a record-breaking quarter in a more than challenging geopolitical environment. Our Carragelose products continue their strong growth path and our partners around the globe are prepared to stock up as needed. SARS-CoV-2 is becoming endemic and common respiratory viruses have a comeback so that the need for broad-band virus blocking products will continue. The strength of our products resulted in the new partnership with Hanmi Pharmaceutical Co., Ltd., one of the largest South Korean pharmaceutical companies,” said Dr. Andreas Grassauer, Marinomed’s CEO. “With our OTC products as a successful pillar, we now will focus the expertise we gained with Carragelose and Marinosolv to harness the full potential of our technologies and develop medicines for indications in virology and immunology that currently lack adequate treatment options. Together with a scientific board of high-profile ophthalmologists, we have identified herpetic stromal keratitis, a rare eye disease that can cause blindness as an ideal indication to fully take advantage of the capabilities of our product candidate Tacrosolv, a fully solubilized formulation of the macrolide immunosuppressant tacrolimus. We demonstrated the anti-inflammatory property of the product candidate in a clinical phase II trial and thus laid the basis to explore its full potential. Our Tacrosolv eyedrops thus promise significant benefits for the treatment of herpetic stromal keratitis and we hope to help patients affected by this condition in the future.”
The full press release is available as download here: